Lixte Biotechnology Holdings Inc — Cash Flow (NASDAQ:LIXT)

Financials

Cash from operating activities 2.13 M-4.14 M-4.61 M-4.29 M-3.16 M -2.58 M Cash from investing activities ————— — Cash from financing activities 4.6 M3.9 M5.14 M3.14 M0 6.47 M Free cash flow 2.13 M-4.14 M-4.61 M-4.29 M-3.16 M -2.58 M

新闻

LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary

LIXTE expands clinical trial for ovarian cancer treatment

Lixte生物科技在430万美元直接发行后股价下跌

斯巴达资本担任Lixte 430万美元融资的配售代理

Lixte Biotechnology stock falls after $4.3 million direct offering

Spartan Capital acts as placement agent in Lixte’s $4.3 million offering

Lixte生物科技股价在430万美元直接融资后下跌

Lixte Biotechnology stock falls after $4.3 million direct offering

Lixte Biotechnology raises $4.3 million in registered direct offering

Lixte生物科技股东批准董事会提名人选和股票计划修订案

Lixte Biotechnology shareholders approve board nominees and stock plan amendment

Lixte生物科技股价在收购英国Liora后下跌